Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/32252
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSoltanzadeh, J-
dc.contributor.authorSahebjamnia, N-
dc.contributor.authorKhosroshahi, EM-
dc.contributor.authorBouguerra, A-
dc.date.accessioned2025-10-31T10:37:14Z-
dc.date.available2025-10-31T10:37:14Z-
dc.date.issued2023-11-18-
dc.identifierORCiD: Javad Soltanzadeh https://orcid.org/0000-0003-3176-8816-
dc.identifierORCiD: Navid Sahebjamnia https://orcid.org/0000-0001-5727-9477-
dc.identifierArticle number: 102903-
dc.identifier.citationSoltanzadeh, J. et al. (2023) 'Commercializing Covid-19 diagnostic technologies: A review of challenges, success factors, and insights from the profiting from innovation framework', Technovation, 130, 102903, pp. 1 - 21. doi: 10.1016/j.technovation.2023.102903.en_US
dc.identifier.issn0166-4972-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/32252-
dc.descriptionData availability: The data that has been used is confidential.en_US
dc.description.abstractEvidence shows that only a few newly developed diagnostic technologies to control and mitigate the recent health crisis- Covid-19 pandemic, have been successfully commercialized. Building on this, we review systematically the literature on the challenging and success factors of the commercialization of Covid-19 diagnostic technologies. In so doing, we draw on the six components of the Profiting From Innovation (PFI) framework, introduced by Teece (1986, 2006, 2018), including networking, supply chain, competitive manufacturing, services, appropriability regimes, and complementary technology, to provide major insights into technology commercialization challenges and success factors for Covid-19 diagnosis technologies. Also, the inductive approach is used to extract other challenges that were not addressed by the PFI framework. Our review makes significant theoretical contributions to innovation management (PFI framework) and crisis management research, and also draws policy implications. We also provide useful directions for future research.en_US
dc.format.extent1 - 21-
dc.format.mediumPrint-Electronic-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 International-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.subjecttechnology commercializationen_US
dc.subjectprofiting from innovationen_US
dc.subjectCovid-19 diagnostic technologyen_US
dc.subjectgrand challengesen_US
dc.titleCommercializing Covid-19 diagnostic technologies: A review of challenges, success factors, and insights from the profiting from innovation frameworken_US
dc.typeArticleen_US
dc.date.dateAccepted2023-10-20-
dc.identifier.doihttps://doi.org/10.1016/j.technovation.2023.102903-
dc.relation.isPartOfTechnovation-
pubs.publication-statusPublished-
pubs.volume130-
dc.identifier.eissn1879-2383-
dc.rights.licensehttps://creativecommons.org/licenses/by-nc-nd/4.0/legalcode.en-
dcterms.dateAccepted2023-10-20-
dc.rights.holderElsevier Ltd.-
Appears in Collections:Brunel Business School Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2023 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ (see: https://www.elsevier.com/about/policies/sharing ).819.64 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons